Interneuron, Boehringer Ingelheim Pharmaceuticals Inc. deal

Boehringer Ingelheim will manufacture IPIC's Redux dexfenfluramine, which is under review by the FDA. IPIC will provide the active ingredient of dexfenfluramine to Boehringer Ingelheim, which will manufacture 15 mg capsules for sale by IPIC and marketing partner Wyeth-Ayerst. ...